Você procurou por: airexar (Inglês - Maltês)

how does airexar spiromax work?
kif jaħdem airexar spiromax?

why is airexar spiromax approved?
għaliex ġie approvat airexar spiromax?

how has airexar spiromax been studied?
kif ġie studjat airexar spiromax?

other information about airexar spiromax
informazzjoni oħra dwar airexar spiromax

airexar spiromax is a ‘hybrid medicine’.
airexar spiromax huwa ‘mediċina ibrida’.

what is airexar spiromax and what is it used for?
x’inhu airexar spiromax u għal xiex jintuża?

airexar spiromax can only be obtained with a prescription.
airexar spiromax jista’ jinkiseb biss b’riċetta ta’ tabib.

what are the benefits and risks of airexar spiromax?
x’inhuma l-benefiċċji u r-riskji ta’ airexar spiromax?

the committee recommended that airexar spiromax be approved for use in the eu.
il-kumitat irrakkomanda li airexar spiromax ikun approvat għall-użu fl-ue.

it is not intended to provide practical advice on how to use airexar spiromax.
dan mhux intiż biex jipprovdi konsultazzjoni prattika dwar l-użu ta’ airexar spiromax.

airexar spiromax is available as an inhalation powder in a portable inhaler device.
airexar spiromax huwa disponibbli bħala trab għall-inalazzjoni f’inalatur portabbli.

what measures are being taken to ensure the safe and effective use of airexar spiromax?
x’miżuri qegħdin jitteħdu biex jiġi żgurat l-użu sigur u effettiv ta’ airexar spiromax?

this is a summary of the european public assessment report (epar) for airexar spiromax.
dan huwa sommarju tar-rapport pubbliku ewropew ta’ valutazzjoni (epar) għal airexar spiromax.

for practical information about using airexar spiromax, patients should read the package leaflet or contact their doctor or pharmacist.
għal informazzjoni prattika dwar l-użu ta’ airexar spiromax, il-pazjenti għandhom jaqraw il-fuljett ta’ tagħrif jew jikkuntattjaw lit-tabib jew spiżjar tagħhom.

recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of airexar spiromax have been included in the summary of product characteristics and the package leaflet.
fis-sommarju tal-karatteristiċi tal-prodott u fil-fuljett ta’ tagħrif ġew inklużi r-rakkomandazzjonijiet u l- prekawzjonijiet li għandhom ikunu segwiti mill-professjonisti fil-qasam tal-kura tas-saħħa u mill- pazjenti għall-użu sigur u effettiv ta’ airexar spiromax.

because airexar spiromax is a hybrid medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
minħabba li airexar spiromax huwa mediċina ibrida u huwa bijoekwivalenti għall-mediċina ta’ referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta’ referenza.

in copd, airexar spiromax is used in adults who have had exacerbations (flare–ups) of the disease in the past and have significant symptoms despite regular treatment.
f’copd, airexar spiromax jintuża f’adulti li fil-passat kellhom aggravar tal-marda u li għandhom sintomi sinifikanti minkejja kura regolari.

airexar spiromax is a medicine used for the regular treatment of adults with severe asthma and for the relief of symptoms of chronic obstructive pulmonary disease (copd, a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty in breathing).
airexar spiromax huwa mediċina li tintuża għall-kura regolari ta’ adulti b’ażma severa u għas-serħan mis-sintomi ta’ mard pulmonari ostruttiv kroniku (copd, marda fit-tul li fiha l-passaġġi tan-nifs u l- boroż tal-arja ġewwa l-pulmuni ssirilhom il-ħsara jew jisfaw imblokkati, u dan iwassal għal diffikultà fit- teħid tan-nifs).